CN110072526A - 治疗癌症的激酶抑制剂化合物、组合物和方法 - Google Patents

治疗癌症的激酶抑制剂化合物、组合物和方法 Download PDF

Info

Publication number
CN110072526A
CN110072526A CN201780062024.1A CN201780062024A CN110072526A CN 110072526 A CN110072526 A CN 110072526A CN 201780062024 A CN201780062024 A CN 201780062024A CN 110072526 A CN110072526 A CN 110072526A
Authority
CN
China
Prior art keywords
alkyl
mmol
nmr
dmso
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780062024.1A
Other languages
English (en)
Chinese (zh)
Inventor
A·C·达尔
R·L·卡根
A·P·斯柯普顿
M·园下
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School of Medicine at Mount Sinai filed Critical Icahn School of Medicine at Mount Sinai
Publication of CN110072526A publication Critical patent/CN110072526A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201780062024.1A 2016-08-17 2017-08-17 治疗癌症的激酶抑制剂化合物、组合物和方法 Pending CN110072526A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376138P 2016-08-17 2016-08-17
US62/376,138 2016-08-17
PCT/US2017/047383 WO2018035346A1 (en) 2016-08-17 2017-08-17 Kinase inhibitor compounds, compositions, and methods of treating cancer

Publications (1)

Publication Number Publication Date
CN110072526A true CN110072526A (zh) 2019-07-30

Family

ID=61197083

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780062024.1A Pending CN110072526A (zh) 2016-08-17 2017-08-17 治疗癌症的激酶抑制剂化合物、组合物和方法

Country Status (6)

Country Link
US (2) US10519113B2 (enExample)
EP (1) EP3500257B1 (enExample)
JP (1) JP2019528279A (enExample)
CN (1) CN110072526A (enExample)
CA (1) CA3034332A1 (enExample)
WO (1) WO2018035346A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113402456A (zh) * 2020-03-16 2021-09-17 深圳大学 一种抗肿瘤药物以及一种化合物或其药学上可接受的盐在抗肿瘤药物中的应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108440404A (zh) * 2018-05-08 2018-08-24 西安凯伦生物科技有限公司 具有多重激酶抑制作用的抗肿瘤药物及其制备方法和应用
CN111362871B (zh) * 2018-12-25 2022-05-17 北京福元医药股份有限公司 取代的吡啶-2-甲酰胺类化合物及其用途
CN114207437B (zh) 2020-02-27 2024-05-28 国立大学法人北海道大学 筛选抗癌剂的方法和用于治疗胰腺癌的激酶抑制剂的组合药物
MX2022014020A (es) * 2020-05-08 2023-02-16 Georgiamune Llc Moduladores de akt3.
US20230404985A1 (en) * 2020-11-02 2023-12-21 Icahn School Of Medicine At Mount Sinai Methods of treating tumors and cancers having dysregulated wnt signaling pathways
KR102710925B1 (ko) * 2021-06-01 2024-09-27 부산대학교 산학협력단 신규 스퀘어아마이드 유도체 및 이의 용도
WO2025083280A1 (en) * 2023-10-19 2025-04-24 Universitat De Barcelona Sorafenib analogs for use in the treatment of cancer

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1630638A (zh) * 2002-02-11 2005-06-22 拜耳制药公司 作为激酶抑制剂的芳基脲类化合物
CN1839126A (zh) * 2003-02-28 2006-09-27 拜耳制药公司 用于治疗癌症和其它病症的新的氰基吡啶衍生物
CN1856469A (zh) * 2003-07-23 2006-11-01 拜尔医药品股份有限公司 用于治疗和预防疾病和疾病症状的氟代ω－羧芳基二苯基脲
WO2007075650A2 (en) * 2005-12-21 2007-07-05 Bayer Healthcare Ag Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
CN101048140A (zh) * 2004-08-27 2007-10-03 拜耳制药公司 用于治疗癌症的新药物组合物
CN100360507C (zh) * 1997-12-22 2008-01-09 拜尔有限公司 用取代杂环脲抑制raf激酶
CN101260106A (zh) * 2007-03-06 2008-09-10 中国药科大学 Raf激酶抑制剂及其制备方法和用途
CN101541977A (zh) * 2006-09-19 2009-09-23 诺瓦提斯公司 用于raf抑制剂的靶向调节、效力、诊断和/或预后的生物标志物
WO2011046991A2 (en) * 2009-10-15 2011-04-21 Gilead Connecticut, Inc. Certain substituted ureas as modulators of kinase activity
CN103508961A (zh) * 2012-06-26 2014-01-15 中美冠科生物技术（太仓）有限公司 抗肿瘤药物
WO2015051149A1 (en) * 2013-10-04 2015-04-09 The Trustees Of Columbia University In The City Of New York Sorafenib analogs and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235576B1 (en) * 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2004014870A1 (en) 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes
EP1608639A2 (en) * 2003-02-28 2005-12-28 Bayer Pharmaceuticals Corporation Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
PT1636585E (pt) * 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
CA2531485C (en) * 2003-07-07 2013-03-26 Merck Patent Gmbh Malonamide derivatives
US20090012091A1 (en) * 2007-07-02 2009-01-08 Kinagen, Inc. Oximide derivatives and their therapeutical application
CN101723890B (zh) * 2008-10-10 2011-11-23 中国科学院成都生物研究所 芳基硫脲及其制备方法和用途
JP2011063516A (ja) * 2009-09-15 2011-03-31 Daiichi Sankyo Co Ltd アミド誘導体
CA2826277A1 (en) * 2011-02-14 2012-08-23 The Regents Of The University Of California Sorafenib derivatives as seh inhibitors
US9216950B2 (en) * 2011-08-03 2015-12-22 National Taiwan University Agonists of Src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same
US9090617B1 (en) 2011-08-03 2015-07-28 National Taiwan University Agonists of Src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same
WO2014007998A1 (en) * 2012-07-06 2014-01-09 The Regents Of The University Of California SORAFENIB DERIVATIVES AS p21 INHIBITORS

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100360507C (zh) * 1997-12-22 2008-01-09 拜尔有限公司 用取代杂环脲抑制raf激酶
CN1630638A (zh) * 2002-02-11 2005-06-22 拜耳制药公司 作为激酶抑制剂的芳基脲类化合物
CN1839126A (zh) * 2003-02-28 2006-09-27 拜耳制药公司 用于治疗癌症和其它病症的新的氰基吡啶衍生物
CN1856469A (zh) * 2003-07-23 2006-11-01 拜尔医药品股份有限公司 用于治疗和预防疾病和疾病症状的氟代ω－羧芳基二苯基脲
CN101048140A (zh) * 2004-08-27 2007-10-03 拜耳制药公司 用于治疗癌症的新药物组合物
WO2007075650A2 (en) * 2005-12-21 2007-07-05 Bayer Healthcare Ag Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
CN101541977A (zh) * 2006-09-19 2009-09-23 诺瓦提斯公司 用于raf抑制剂的靶向调节、效力、诊断和/或预后的生物标志物
CN101260106A (zh) * 2007-03-06 2008-09-10 中国药科大学 Raf激酶抑制剂及其制备方法和用途
WO2011046991A2 (en) * 2009-10-15 2011-04-21 Gilead Connecticut, Inc. Certain substituted ureas as modulators of kinase activity
CN103508961A (zh) * 2012-06-26 2014-01-15 中美冠科生物技术（太仓）有限公司 抗肿瘤药物
WO2015051149A1 (en) * 2013-10-04 2015-04-09 The Trustees Of Columbia University In The City Of New York Sorafenib analogs and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GUO-BO LI等: "LEADOPT: an automatic tool for structure-based lead optimization, and its application in structural optimizations of VEGFR2 and SYK inhibitors", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 *
MASAHIRO SONOSHITA 等: "A Whole Animal Platform to Advance A Clinical Kinase Inhibitor Into New Disease Space", 《NATURE CHEMICAL BIOLOGY》 *
ZHANG L.ET.AL: "Convenient Synthesis of Sorafenib and Its Derivatives", 《SYNTHETIC COMMUNICATIONS》 *
姚建文 等: "多靶点抗肿瘤药物索拉非尼结构改造的研究进展", 《药学学报》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113402456A (zh) * 2020-03-16 2021-09-17 深圳大学 一种抗肿瘤药物以及一种化合物或其药学上可接受的盐在抗肿瘤药物中的应用
CN113402456B (zh) * 2020-03-16 2023-03-03 深圳大学 一种抗肿瘤药物以及一种化合物或其药学上可接受的盐在抗肿瘤药物中的应用

Also Published As

Publication number Publication date
CA3034332A1 (en) 2018-02-22
US11066370B2 (en) 2021-07-20
EP3500257A4 (en) 2020-01-22
US20190202789A1 (en) 2019-07-04
US20200325103A1 (en) 2020-10-15
EP3500257B1 (en) 2025-07-02
US10519113B2 (en) 2019-12-31
EP3500257A1 (en) 2019-06-26
WO2018035346A1 (en) 2018-02-22
JP2019528279A (ja) 2019-10-10
WO2018035346A8 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
US11066370B2 (en) Kinase inhibitor compounds, compositions, and methods of treating cancer
TWI798446B (zh) 作為核轉運調節劑之化合物及其用途
CA2969090C (en) Triazolopyrimidine compounds and uses thereof
RU2719428C2 (ru) Индазольные соединения в качестве ингибиторов киназы fgfr, их получение и применение
KR101586112B1 (ko) 카바졸 화합물 및 이 화합물의 치료학적 용도
JP5881704B2 (ja) Ｎａｍｐｔの阻害のための新規な化合物及び組成物
ES2753386T3 (es) Derivados de 2-hidroxi-1-{4-[(4-fenil)fenil]carbonil}piperazin-1-il}etano-1-ona y compuestos relacionados como inhibidores de sintasa de ácido graso (FASN) para el tratamiento del cáncer
KR102449712B1 (ko) 아미노티아졸 화합물 및 이의 용도
CA3124678A1 (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
CA3124952A1 (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
KR20200011965A (ko) Map4k1의 신규한 억제제
KR20140027366A (ko) Nampt의 억제를 위한 신규 화합물 및 조성물
CN106883213A (zh) 一种新型egfr和alk激酶的双重抑制剂
KR20170106452A (ko) 4Ｈ-피롤로［3,2-ｃ］피리딘-4-온 유도체
WO2013170774A1 (zh) 具有抗肿瘤活性的乙炔衍生物
JP2018508563A (ja) Ｕｓｐ７阻害剤化合物及び使用方法
CN109789144B (zh) 蛋白激酶调节剂
Reutershan et al. Discovery of MK-4688: an efficient inhibitor of the HDM2–p53 protein–protein interaction
CN106349228B (zh) 取代的喹唑啉酮类化合物及其制备方法和用途
JP6386585B2 (ja) プロテインキナーゼのインヒビターとしてのフロピリジン
WO2017097216A9 (zh) 五元杂环酰胺类wnt通路抑制剂
CN108601773A (zh) 作为pi3k/mtor抑制剂的稠合喹啉化合物
WO2012163236A1 (zh) 一种吡啶并硫氮七元环衍生物及其制备方法和应用
CN107428762A (zh) 酞嗪酮衍生物、其制备方法及用途
WO2022171088A1 (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40010493

Country of ref document: HK